Multiple Sclerosis—A Demyelinating Disorder and Its Dental Considerations—A Literature Review with Own Case Report

Multiple sclerosis (MS) is a chronic, autoimmune condition that primarily affects the myelin sheath covering the neurons of the central nervous system, including those of the brain and spinal cord. Although the etiology is not completely understood, various factors, such as genetic infections and environmental background, play a role in the pathogenesis. Repeated active episodes of MS characterized with marked inflammation results in the scarring of particular nerve segments, and eventually results in functional impairment over a period of time. Based on the clinical course of the disease, four clinical types of MS have been identified, with the relapsing–remitting type being the commonest. MS is known to occur more commonly in females in the age group of 20–40 years. Dysarthria, fatigue, muscle spasm, and numbness are the common presenting symptoms of MS. Diagnosis is generally achieved with MRI brain scans, showing demyelination plaques and lumbar puncture. Treatment of MS’s acute phase includes high doses of corticosteroids; whereas preventive treatment of MS includes the prescription of immunosuppressive therapy, including biologics. A large group of MS patients present with oral manifestations, including dysphagia, dysarthria, temporomandibular joint (TMJ) disturbances, facial palsy, and chronic periodontal diseases. Other typical oral manifestations seen in MS patients include trigeminal neuralgia, paresthesia, or orofacial pain. Dental treatment and following drug prescription needs to be tailored to each patient, as there is a possibility of drug interactions. This paper presents a comprehensive, updated review of MS, with emphasis on oral manifestations and dental considerations. Additionally, it presents a case of a 40-year-old female diagnosed with MS that was presented to a dental hospital. The report discusses the oral manifestations and dental management.

[1]  V. Ronsivalle,et al.  Prevalence of Temporomandibular Disorders in subjects affected by Parkinson Disease: a systematic review and metanalysis. , 2023, Journal of oral rehabilitation.

[2]  L. Fiorillo,et al.  Economic inequalities and temporomandibular disorders: a systematic review with meta-analysis. , 2023, Journal of oral rehabilitation.

[3]  Sahana Shivakumar,et al.  Impact of temporomandibular disorders on Oral Health Related Quality of Life: A systematic review and meta-analysis. , 2023, Journal of oral rehabilitation.

[4]  L. Fiorillo,et al.  Prevalence of temporomandibular disorders in children and adolescents evaluated with Diagnostic Criteria for Temporomandibular disorders (DC/TMD): A systematic review with meta-analysis. , 2023, Journal of oral rehabilitation.

[5]  Neil Patel,et al.  Pathogenesis and management of multiple sclerosis revisited. , 2022, Disease-a-month : DM.

[6]  Foziah Alshamrani,et al.  Unmet Needs and Treatment of Relapsing-Remitting Multiple Sclerosis in Saudi Arabia: Focus on the Role of Ofatumumab , 2022, Neurology and Therapy.

[7]  A. R. Castro,et al.  Oral Health Status and Multiple Sclerosis: Classic and Non-Classic Manifestations—Case Report , 2022, Diseases.

[8]  R. Bunyan,et al.  Prevalence of Pediatric Onset Multiple Sclerosis in Saudi Arabia , 2021, Multiple sclerosis international.

[9]  N. Alqhtani,et al.  Cortisol in Oral and Maxillofacial Surgery: A Double-Edged Sword , 2021, International journal of dentistry.

[10]  C. Bryant,et al.  Multiple sclerosis and its impact on dental care , 2021, British Dental Journal.

[11]  Z. Khurshid,et al.  Novel Approach to Dental Biofilm Management through Guided Biofilm Therapy (GBT): A Review , 2021, Microorganisms.

[12]  A. Nagarajappa,et al.  Evaluation of temporomandibular disorders among dental students of Saudi Arabia using Diagnostic Criteria for Temporomandibular Disorders (DC/TMD): a cross-sectional study , 2021, BMC oral health.

[13]  A. Rae-Grant,et al.  Diagnosis and Treatment of Multiple Sclerosis: A Review. , 2021, JAMA.

[14]  J. Flores-Rivera,et al.  Cyclophosphamide treatment in active multiple sclerosis , 2021, Neurological Sciences.

[15]  E. Celius,et al.  Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives , 2021, Patient preference and adherence.

[16]  E. Leray,et al.  Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition , 2020, Multiple sclerosis.

[17]  R. Bunyan,et al.  Familial aggregation of multiple sclerosis: Results from the national registry of the disease in Saudi Arabia , 2020, Multiple sclerosis journal - experimental, translational and clinical.

[18]  M. Sghaireen,et al.  Microbiological and Clinical evaluation of Neem gel and Chlorhexidine gel on Dental Plaque and Gingivitis in 20-30 Years Old Adults: A Randomized Parallel-Armed, Double-Blinded Controlled Trial , 2020, Journal of pharmacy & bioallied sciences.

[19]  Z. Khurshid,et al.  BactericidalActivity of Crevicular Polymorphonuclear Neutrophils in Chronic Periodontitis Patients and Healthy Subjects under the Influence of Areca Nut Extract: An In Vitro Study , 2020 .

[20]  H. Ford Clinical presentation and diagnosis of multiple sclerosis. , 2020, Clinical medicine.

[21]  G. Ruoppolo,et al.  Multiple Sclerosis: Impact on Oral Hygiene, Dysphagia, and Quality of Life , 2020, International journal of environmental research and public health.

[22]  M. Etemadifar,et al.  Incidence and prevalence of multiple sclerosis in persian gulf area: A systematic review and meta-analysis. , 2020, Multiple sclerosis and related disorders.

[23]  R. Bunyan,et al.  Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study , 2019, BMC Neurology.

[24]  Akram Ataei,et al.  Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2. , 2019, International journal of physiology, pathophysiology and pharmacology.

[25]  E. Alvarez,et al.  Monoclonal Antibodies in Multiple Sclerosis: Present and Future , 2019, Biomedicines.

[26]  A. Truini,et al.  Trigeminal neuralgia secondary to multiple sclerosis: from the clinical picture to the treatment options , 2019, The Journal of Headache and Pain.

[27]  G. Giovannoni,et al.  Multiple sclerosis – a review , 2018, European journal of neurology.

[28]  M. Filippi,et al.  Multiple sclerosis , 2018, Nature Reviews Disease Primers.

[29]  F. Lublin,et al.  Clinical Course of Multiple Sclerosis. , 2018, Cold Spring Harbor perspectives in medicine.

[30]  Nikolaos A Patsopoulos,et al.  Genetics of Multiple Sclerosis: An Overview and New Directions. , 2018, Cold Spring Harbor perspectives in medicine.

[31]  A. White,et al.  Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review. , 2017, Clinical therapeutics.

[32]  Anders Larsson,et al.  Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 , 2017, The Lancet Neurology.

[33]  H. Algahtani,et al.  Quality of life among multiple sclerosis patients in Saudi Arabia , 2017, Neurosciences.

[34]  M. Nakajima,et al.  Anesthetic Management of a Patient With Multiple Sclerosis. , 2017, Anesthesia progress.

[35]  G. Spagnuolo,et al.  Interface Between MTA and Dental Bonding Agents: Scanning Electron Microscope Evaluation , 2017, Journal of International Society of Preventive & Community Dentistry.

[36]  DrKumarChandan Srivastava,et al.  JOURNEY TOWARDS THE 3D DENTAL IMAGING- THE MILESTONES IN THE ADVANCEMENT OF DENTAL IMAGING. , 2016 .

[37]  S. Razavi,et al.  Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy , 2016, Cell journal.

[38]  E. Granieri,et al.  The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study , 2016, PloS one.

[39]  K. Burchiel,et al.  Atypical facial pain in multiple sclerosis caused by spinal cord seizures: a case report and review of the literature , 2016, Journal of Medical Case Reports.

[40]  L. Călugăru,et al.  Evoked Potentials in Multiple Sclerosis Diagnosis and Management , 2016, Current health sciences journal.

[41]  O. Ciccarelli,et al.  MRI CRITERIA FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS: MAGNIMS CONSENSUS GUIDELINES , 2016, The Lancet Neurology.

[42]  G-Q Zhang,et al.  Oral and craniofacial manifestations of multiple sclerosis: implications for the oral health care provider. , 2015, European review for medical and pharmacological sciences.

[43]  M. Rovaris,et al.  Drug therapy for multiple sclerosis , 2014, Canadian Medical Association Journal.

[44]  David H. Miller,et al.  Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging , 2014, The Lancet Neurology.

[45]  Jeffrey A. Cohen,et al.  Defining the clinical course of multiple sclerosis: the 2013 revisions. , 2014, Neurology.

[46]  A. Ascherio Environmental factors in multiple sclerosis , 2013, Expert review of neurotherapeutics.

[47]  J. Sheu,et al.  Association between multiple sclerosis and chronic periodontitis: a population‐based pilot study , 2013, European journal of neurology.

[48]  P. Rieckmann,et al.  Multiple sclerosis in the Arabian Gulf countries: a consensus statement , 2013, Journal of Neurology.

[49]  S. Danesh-Sani,et al.  Clinical assessment of orofacial manifestations in 500 patients with multiple sclerosis. , 2013, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[50]  Hans Lassmann,et al.  Progressive multiple sclerosis: pathology and pathogenesis , 2012, Nature Reviews Neurology.

[51]  D. Grover,et al.  Systemic antibiotic therapy in periodontics , 2012, Dental research journal.

[52]  E. Martínez-Pérez,et al.  Oral health status of a population with multiple sclerosis , 2011, Medicina oral, patologia oral y cirugia bucal.

[53]  Rock Heyman,et al.  Multiple Sclerosis: Pathogenesis and Treatment , 2011, Current neuropharmacology.

[54]  F. Ashtari,et al.  Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β-1α: A randomized controlled trial , 2011, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[55]  K. Stockl,et al.  Improving patient self-management of multiple sclerosis through a disease therapy management program. , 2010, The American journal of managed care.

[56]  K. Rammohan Cerebrospinal fluid in multiple sclerosis , 2009, Annals of Indian Academy of Neurology.

[57]  D. Ontaneda,et al.  Management of acute exacerbations in multiple sclerosis , 2009, Annals of Indian Academy of Neurology.

[58]  J. Epstein,et al.  Multiple sclerosis: an update for oral health care providers. , 2009, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[59]  G. Cruccu,et al.  Trigeminal neuralgia and pain related to multiple sclerosis , 2009, PAIN®.

[60]  A J Thompson,et al.  Multiple sclerosis: diagnosis and the management of acute relapses , 2005, Postgraduate Medical Journal.

[61]  H. Weiner Immunosuppressive treatment in multiple sclerosis , 2004, Journal of the Neurological Sciences.

[62]  Polman,et al.  Drug treatment of multiple sclerosis , 2000, The Western journal of medicine.

[63]  D. Chemaly,et al.  Oral and maxillofacial manifestations of multiple sclerosis. , 2000, Journal.

[64]  H. Huggins,et al.  Cerebrospinal fluid protein changes in multiple sclerosis after dental amalgam removal. , 1998, Alternative medicine review : a journal of clinical therapeutic.

[65]  G. Seymour,et al.  A preliminary study into the dental health status of multiple sclerosis patients. , 1993, Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry.

[66]  M. Mumenthaler [Multiple sclerosis, diagnosis and differential diagnosis]. , 1967, Praxis.

[67]  T. Fog,et al.  [Multiple sclerosis; review]. , 1954, Maanedsskrift for praktisk laegegerning og social Medicin.

[68]  M. Kaminska,et al.  Multiple Sclerosis and related disorders. , 2022, Handbook of Clinical Neurology.

[69]  M. Stasiołek,et al.  Differential diagnosis of multiple sclerosis and other inflammatory CNS diseases. , 2020, Multiple sclerosis and related disorders.

[70]  T. Alsaadi,et al.  Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. , 2019, Multiple sclerosis and related disorders.

[71]  T. Olsson,et al.  Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis , 2017, Nature Reviews Neurology.